The role of immunotherapy for urological tumours

British Journal of Urology

Volumn 79, Issue 3, 1997, Pages 307-316

  Hrouda, D ^a,e   Muir, G H ^a,b   Dalgleish, A G ^b,c,d  

^a Department of Urology ^*

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; INTERFERON; INTERLEUKIN 2;

ARTHRALGIA; BLADDER CANCER; CANCER IMMUNOTHERAPY; CYSTITIS; CYTOPENIA; EPIDIDYMITIS; FEVER; HEMATURIA; HEPATITIS; KIDNEY ABSCESS; KIDNEY CARCINOMA; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; RASH; REVIEW; SEPSIS; URETER OBSTRUCTION; URINARY TRACT TUMOR;

EID: 0031397247     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00301.x     Document Type: Review

References (100)

1. Burnet FM. Immunological Surveillance. Oxford: Pergamon Press, 1970
2. Coley WB. Treatment of inoperable malignant tumours with the toxins of erysipelas and the Bacillus prodigosus. Trans Am Surg Assoc 1894: 12: 183
3. Morton DL, Hunt KK. Bauer RL, Lee JD. Immunotherapy by active immunization of the host using non-specific agents. In De Vita DT, Hellman S. Rosenberg SA. eds. The Biologic Therapy of Cancer. Philadelphia: Lippincott, 1991: 627-50
4. Morales A. Eidinger D. Bruce AW. Intracavitary Bacillus Calmette-Guèrin in the treatment of superficial bladder tumors. J Urol 1976: 116: 180-3
5. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281-355
6. Blades RA. Keating PJ. McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995: 46: 681-6; discussion 686-7
7. Luboldt H-J, Kubens BS, Rubben H. Grosse-Wilde H. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 1996; 56: 826-30
8. Nouri AM. Hussein RF, Oliver RT. The frequency of major histocompatibility complex antigen abnormalities in urological tumours and their correction by gene transfection or cytokine stimulation. Cancer Gene Ther 1994: 1: 119-2 3
9. Kavoussi LR, Brown EJ. Ritchey JK. Ratliff TL. Fibronectinmediated Calmette-Guèrin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 1990; 85: 62-7
10. Becich MJ. Carroll S, Ratliff TL. Internalization of bacille Calmette-Guèrin by bladder tumor cells. J Urol 1991; 145: 1316-24
11. Lattime EC, Cornelia LG. McCue PA. Murine bladder carcinoma cells present antigen to BCG-specilic CD4 + T-cells. Cancer Res 1992; 52: 4286-90
12. Bohle A. Gerdes J. Ulmer A), Hofstetter AG. Flad HD. Effects of local bacillus Calmette-Guèrin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990: 144: 53-8
13. 3 Prescott S, James K. Hargreave TB, Chisholm GD. Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992: 147: 1636-42
14. Ratliff TL, Ritchey JK. Yuan JJ. Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993: 150: 1018-23
15. 5 Reijke TMD, Boer ECD, Kurth KH. Schamhart DHJ. Urinary cytokines during intravesical bacillus Calmette-Guèrin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996; 155: 477-82
16. Kaempfer R, Gerez L, Farbstein H et al. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 1996; 14: 1778-86
17. Lamm DL. Riggs DR. Traynelis CL. Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995: 153: 1444-50
18. Tolley DA, Parmar MKB. Grigor KM. Lallemand G. party MRCsbcw. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with years of follow up. J Urol 1996: 155: 12338
19. Lamm DL. Bacillus Calmette-Guèrin immunotherapy for bladder cancer. J Urol 1985: 134: 40-7
20. Herr HW. Pinsky CM. Whitmore WF Jr et al. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors. Urology 1985: 25: 119-23
21. Herr HW. Pinsky CM. Whitmore WF Jr et al. Long-term effect of intravesical bacillus Calmette-Guèrin on flat carcinoma in situ of the bladder. J Urol 1986: 135: 265-7
22. Pagano F, Bassi P, Milani C et al A low dose bacillus Calmette-Guèrin regimen in superficial bladder cancer therapy: is it effective? J Urol 1991; 146: 32-5
23. Melekos MD, Chionis H, Pantazakos A el al. Intravesical bacillus Calmette-Guèrin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol 1993: 149: 744-8
24. Rubben H, Lutzeyer W. Fischer N et al. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988; 139: 283-5
25. 5 Brosman SA. Experience with bacillus Calmette-Guèrin in patients with superficial bladder carcinoma. J Urol 1982: 128: 27-30
26. DeBruyne FM, van der Meijden AP, Geboers AD et al. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial. Urology 1988; 31 (Suppl 3): 20-5
27. Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L Jr et al. Bacillus Calmette-Guèrin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990: 143: 502-6
28. Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guèrin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205-9
29. Rintala E, Jauhiainen K, Alfthan O et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guèrin) in superficial bladder cancer. Eur Urol 1991; 20: 19-25
30. Witjes JA, van der Meijden AP. Witjes WP et al. A randomised prospective study comparing intravesical instillations of mitomycin-C. BCG-Tice, and BCG-RIVM in pTa-pTl tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. Eur J Cancer 1993; 29A: 1672-6
31. Lamm DL, Crawford ED, Blumenstein B et al. SWOG 8795: a randomized comparison of bacillus CalmetteGuèrin and mitomycin C prphylaxis in stage Ta and Tl transitional cell carcinoma of the bladder. J Urol 1993; 149: 282A
32. Herr HW, Laudone VP, Badalament RA et al. Bacillus Calmette-Guèrin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450-5
33. Fellows GJ. Parmar MK. Grigor KM et al. Marker tumour response to Evans and Pasteur bacille Calmette-Guèrin in multiple recurrent pTa/pTl bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br J Urol 1994: 73: 639-44
34. Lamm DL, DeHaven JI. Shriver J, Sarosdy MF. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guèrin versus intravesical bacillus Calmette-Guèrin in superficial bladder cancer. J Urol 1991; 145: 738-40
35. Haaff EO, Dresner SM. Ratliff TL. Catalona WJ. Two courses of intravesical bacillus Calmette-Guèrin for transitional cell carcinoma of the bladder. J Urol 1986; 136: 820-4
36. Lamm DL. Optimal BCG treatment of superficial bladder cancer as defined by American trials. Eur Urol 1992; 21 (Suppl 2): 12-6
37. Morales A. JCN. Dose response of BCG in superficial bladder cancer. J Urol 1990; 143: 340A
38. Van der Meijden APM, Hall RR, Pavone Macaluso M et al. Marker tumour response to the sequential combination of intravesical therapy with mitomycin C and BCG-RIVM in multiple superficial bladder tumours. Eur Urol 1996: 29: 199-203
39. Grange JM, Stanford JL. Rook GA. Tuberculosis and cancer: parallels in host responses and therapeutic approaches? Lancet 1995: 345: 1350-2
40. Orihuela E. Herr HW. Pinsky CM, Whitmore WF Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 1987; 60: 326-33
41. Lamm DL, van der Meijden PM. Morales A et al. Incidence and treatment of complications of bacillus CalmetteGuèrin intravesical therapy in superficial bladder cancer. J Urol 1992; 147: 596-600
42. Steg A, Leleu C. Debre B. Boccon-Gibod L, Sicard D. Systemic bacillus Calmette-Guèrin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res 1989; 310: 325-34
43. Lamm DL. Complications of bacillus Calmette-Guèrin immunotherapy. Urol Clin North Am 1992: 19: 565-72
44. Bohle A, Balck F, Wietersheim Jv, Jocham D. The quality of life during intravesical bacillus Calmette-Guèrin therapy. }Urol 1996; 155: 1221-6
45. Jurincic-Winkler C, Metz KA, Beuth J, Engelmann U, Klippel KF. Immunohistological findings in patients with superficial bladder carcinoma after intravesical instillation of keyhole limpet haemocyanin. Br] Urol 1995; 76: 702-7
46. Olsson CA, Chute R, Rao CN. Immunologie reduction of bladder cancer recurrence rate. J Urol 1974; 111: 173-6
47. Jurincic CD, Engelmann U, Gasch J, Klippel KF. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 1988: 139: 723-6
48. Glashan RW. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 1990; 144: 658-61
49. Tubaro A, Stoppacciaro A, Velotti F et al. Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2. Eur Urol 1995; 28: 297-303
50. Fairlamb DJ. Spontaneous regression of metastases of renal cancer: a report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 1981: 47: 2102-6
51. deKernion JB. Sarna G. Figlin R, Lindner A. Smith RB. The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 1983: 130: 1063-6
52. Figlin RA, deKernion JB. Mukamel E et al Recombinant Interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol 1988: 6: 1604-10
53. Kirkwood JM. Harris JE, Vera R et ai A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 1985: 45: 863-71
54. Umeda T, Niijima T. Phase study of alpha Interferon on renal cell carcinoma. Summary of thrse collaborative trials. Cancer 1986: 58: 1231-5
55. Minasian LM, Motzer RJ, Gluck E et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 1 59 patients with long-term iollow-up. J Clin Oncol 1993; 11: 1368-75
56. Sarna G. Figlin R, de Kernion J. Interferon in renal cell carcinoma. The IICEA experience. Cancer 1 987: 59 (Suppl 3): 610-2
57. Muss HB. Interferon therapy for renal :ell carcinoma. Sem Oncol 1987: 14 (Suppl 2): 36-42
58. Lotze MT. Robb RJ. Sharrow SO, Frana EW. Rosenberg SA. Systemic administration of interleukin-2 in humans. J Bio/ Resp Mod 1984: : 475-82
59. Rosenberg SA. Yang JC. Topalian SE et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 [see comments]. JAMA 1994: 271: 907-13
60. Taneja SS. Pierce W. Figlin R, Belldegrun A. Management of disseminated kidney cancer. Urol Clin North Am 1994; 21: 625-37
61. Yang JC. Topalian SE, Parkinson D et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metasiatic renal cell carcinoma: an interim report. J Clin Oiicol 1994; 12: 1572-6
62. Brunda MJ, Tarnowski D. Davatelis V. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int! J Cancer 1986: 37: 787-93
63. ligo M. Sakurai M. Tamura T, Saijo N. Hoshi A. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant Interferon, on various syngeneic murine tumors. Cancer Res 19S8: 48: 260-4
64. Cameron RB, Mclntosh JK. Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic métastases. Cancer Res 1988: 48: 5810-7
65. Thomas H, Barton C, Saini A, Dalgleish A, Waxman J. Sequential interleukin-2 and alpha Interferon for renal cell carcinoma and melanoma. Eur J Cancer 1992: 28A(6-7): 1047-9
66. Atkins MB. Sparano J, Fisher RI et al. Randomized phase trial of high-dose interleukin-2 either alone or in combination with Interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993; 11: 661-70
67. Marincola FM. White DE, Wise AP, Rosenberg SA. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995; 13: 1110-22
68. Sella A. Logothetis CJ. Fitz K et al. Phase study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol 1992: 147: 573-7
69. Atzpodien J. Kirchner H, Hanninen EL et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur }Cancer 1993; 29A (Suppl 5): S6-8
70. Sella A. Zukiwski A. Robinson E. Interleukin-2 with interferon alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Prof Am Soc Clin Oncol 1994; 13: 237
71. Phillips JH. Lanier LL. Dissection of the lymphokineactivated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164: 814-25
72. Rosenberg SA. Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer [published erratum appears in J Natl Cancer Inst 1993: 85: 1091]. J Natl Cancer Inst 1993; 85: 622-32
73. Halapi E, Yamamoto Y, Juhlin C et al. Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas. Cancer Immunol Immunother 1993: 36: 191-7
74. Finke JH. Tubbs R. Connelly B, Pontes E. Montie J. Tumorinfiltrating lymphocytes in patients with renal-cell carcinoma. Ann N Y Acad Sei 1988: 532: 387-94
75. Topalian SL. Solomon D. Avis FP et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988: 6: 839-53
76. Bukowski RM. Sharf'man W, Murthy S et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res 1991; 51: 4199-205
77. Dillman RO. Church C, Oldham RK et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993; 71: 2358-70
78. Belldegrun A. Franklin J. Dorey F et al. Long term survival of 181 patients with metastatic renal cell carcinoma treated with TL-2 based immunotherapy with/without tumor infiltrating lymphocytes. J Urol 1996: 1 55: in press
79. Osband ME, Lavin PT. Babayan RK et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma [see comments]. Lancet 1990: 335: 994-8
80. Graham S. Babayan RK, Lamm DL et al. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. Semin Ural 1993; 11: 27-34
81. Lavin PT. Maar R, Franklin M et al. Autolymphocyte therapy for metastatic renal cell carcinoma: initial clinical results from 335 patients treated in a multisite clinical practice. Transplant Proc 1992; 24: 3059-64
82. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sei USA 1993; 90: 3539-43
83. Marshall F. Jaffee E, Weber C et al. Bioactivity of human BM-CSF gene therapy in metastatic renal carcinoma. J Urol 1996; 155: 582A (Abstract 1087)
84. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am 1993; 20: 247-62
85. 5 Knight BC, Souberbielle BE, Rizzardi GP, Ball SE, Dalgleish AG. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res 1996; 6: 299-306
86. Dekernion JB. Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978: 120: 148-52
87. Montie JE, Stewart BH. Straffon RA et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977; 117: 272-5
88. Marcus SG. Choyke PL. Reiter R et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993; 150: 463-6
89. Wolf JS, Jr., Aronson FR, Small EJ, Carroll PR. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens [see comments]. J Surg Oncol 1994; 55: 7-13
90. Walther MM, Alexander RB, Weiss GH et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 1993; 42: 250-7; discussion 257-8
91. Gittes RF. McCullough DL. Occult carcinoma of the prostate: an oversight of immune surveillance-a working hypothesis. J Urol 1974; 112: 241-4
92. Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumourintiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur 1 Cancer 1994; 30A: 1797-803
93. Guinan P, Toronchi E. Shaw M, Crispin R, Sharifl R. Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology 1982; 20: 401-3
94. Brosman S. Nonspecific immunotherapy in GU cancer. In Crispen R ed., Neoplasm Immunity. Philadelphia: Franklin Institute Press. 1977: 97-107
95. 5 Hrouda D, Dalgleish AG. Gene therapy for prostate cancer. GeneTher 1996; 3: 845-52
96. Vieweg J, Rosenthal FM. Banner)! R et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994; 54: 1760-5
97. Sanda MG, Ayyagari SR, Jaffee EM et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151: 622-8
98. Corman JM, Belldegrun A, Sercarz EE. Nanda NK. Prostate specific antigenic peptides induce T cell proliferation in-vitro: a model for the development of prostate specific tumor vaccines. J Urol 1996; 155: 528A (abstract no. 870)
99. Tjoa B, Erickson S, Barren R 3rd et al. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995; 27: 63-9
100. Tjoa B, Boynton A, Kenny G et al. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996; 28: 65-9